FDA approves expansion of Ozempic label

Novo Nordisk’s (NOV: N) once-weekly drug Ozempic (semaglutide) has had its label expanded by the US Food and Drug Administration (FDA).

The agency approved the Danish drugmaker’s supplemental New Drug Application to market the therapy for the indication of reducing the risk of major adverse cardiovascular (CV) events including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established CV disease.

Rybelsus label update